Discontinuation report EXTAVIA
| Report ID | 152532 |
| Drug Identification Number | 02337819 |
| Brand name | EXTAVIA |
| Common or Proper name | EXTAVIA 30G / VIAL 0.3MG (X15) |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | INTERFERON BETA-1B |
| Strength(s) | 0.3MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | X15 |
| ATC code | L03AB |
| ATC description | IMMUNOSTIMULANTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2022-02-18 |
| Actual discontinuation date | 2022-02-10 |
| Remaining supply date | 2022-08-30 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-02-11 | English | Compare |
| v4 | 2022-02-10 | French | Compare |
| v3 | 2022-02-10 | English | Compare |
| v2 | 2022-01-12 | French | Compare |
| v1 | 2022-01-12 | English | Compare |
Showing 1 to 5 of 5